[STUDY_ID_REMOVED]
Date: 06-FEB-2020
 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 2 of 71 
  
Table of Contents  
 1
 Introduction ............................................................................................................................................. 5  
2 Background and Justification for Clinical Trial  ....................................................................................... 5  
2.1.1  CardioMEMS ™ Clinical Experience  .......................................................................................... 5  
2.1.2  Patient Selection for CardioMEMS™ Therapy  .......................................................................... 6  
2.1.3  Natriuretic Peptides in HF .......................................................................................................... 6  
2.1.4  Clinical Trial Rationale  ............................................................................................................... 7  
3 Device(s) Under Investigation  ................................................................................................................ 7  
 Identification and Description of the Devices under Investigation  ................................................. 7  
3.1.1  Identification  .............................................................................................................................. 7  
3.1.2  Device Description and Intended Purpose  ................................................................................ 8  
3.1.3  Intended Purpose within the Clinical Trial  ................................................................................. 9  
3.1.4  Device Handling and Storage  .................................................................................................... 9  
4 Clinical Trial Design  ............................................................................................................................... 9  
4.1.1  Clinical Trial Duration  ................................................................................................................ 9  
4.1.2  GUIDE -HF Randomized Arm .................................................................................................. 10 
4.1.3  GUIDE -HF Single Arm ............................................................................................................. 10 
 Objectives  .................................................................................................................................... 11 
 Endpoints  ..................................................................................................................................... 11 
4.3.1  GUIDE -HF Randomized Arm .................................................................................................. 11 
4.3.2  GUIDE -HF Single Arm ............................................................................................................. 12 
 Clinical Trial Population  ............................................................................................................... 13 
4.4.1  Inclusion Criteria  ...................................................................................................................... 13 
4.4.2  Exclusion Criteria  ..................................................................................................................... 14 
4.4.3  Enrollment of Medicare Beneficiaries  ...................................................................................... 14 
4.4.4  Historically Underrepresented Demographic Subgroups  ........................................................ 15 
5 Clinical Trial Procedures  ...................................................................................................................... 15 
 Clinical Trial Flow Chart  .............................................................................................................. 16 
 Subject Recruitment  .................................................................................................................... 18 
 Point of Enrollment  ...................................................................................................................... 18 
 Scheduled Procedures  ................................................................................................................ 18 
5.4.1  Screening Procedures  ............................................................................................................. 18 
5.4.2  Informed Consent  .................................................................................................................... 19 
5.4.3  Baseline Procedures  ............................................................................................................... 19 
5.4.4  Implant Procedure  ................................................................................................................... 20 
5.4.5  Randomization  ......................................................................................................................... 21 
5.4.6  Prior to Discharge  .................................................................................................................... 21 
5.4.7  Hemodynamic Management of HF – Treatment Guidance ..................................................... 21 
5.4.8  Patient database (Merlin.net ™) ............................................................................................... 22 
5.4.9  PA Pressure Readings in the Hospital  .................................................................................... 22 
5.4.10  Post-Discharge Subject Phone Contact Requirements  ...................................................... 23 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 3 of 71 
  
5.4.11  Scheduled Follow - ups ........................................................................................................ 24 
5.4.12  Data Viewing After 12 Months  ............................................................................................. 24 
 Unscheduled Visits  ...................................................................................................................... 24 
 Healthcare Economic Data Collection  ......................................................................................... 25 
 Description of Activities Performed by Sponsor Representatives  ............................................... 25 
 Subject Clinical Trial Completion  ................................................................................................. 25 
 Subject Withdrawal  ...................................................................................................................... 25 
 Clinical Trial Committees  ............................................................................................................. 26 
5.10.1  Steering Committee  ............................................................................................................. 26 
5.10.2  Publication Committee......................................................................................................... 26 
5.10.3  Data Safety Monitoring Board (DSMB)  ............................................................................... 26 
5.10.4  CEC  ..................................................................................................................................... 26 
6 Statistical Considerations  ..................................................................................................................... 26 
 GUIDE -HF Randomized Arm ...................................................................................................... 27 
6.1.1  Primary Endpoint  ..................................................................................................................... 27 
6.1.2  Secondary Endpoints  .............................................................................................................. 27 
 GUIDE -HF Single Arm  ................................................................................................................ 29 
6.2.1  Primary Endpoint  ..................................................................................................................... 29 
6.2.2  Secondary Endpoints  .............................................................................................................. 30 
 Justification of Clinical Trial Design  ............................................................................................. 31 
 Multiplicity  .................................................................................................................................... 32 
 Overall Sample Size  .................................................................................................................... 33 
 Statistical Criteria for Termination  ............................................................................................... 33 
 Deviations from Statistical Plan  ................................................................................................... 33 
7 Risks and Benefits  ............................................................................................................................... 33 
 Risks Associated with the Device under Investigation  ................................................................ 33 
7.1.1  Anticipated AEs  ....................................................................................................................... 33 
7.1.2  Anticipated ADEs/SADEs  ........................................................................................................ 34 
7.1.3  Non- AE Device Issue  .............................................................................................................. 35 
 Risk Control Measures  ................................................................................................................ 35 
 Possible interactions with concomitant treatments  ..................................................................... 35 
 Anticipated Benefits  ..................................................................................................................... 35 
 Risk-to-Benefit Rationale  ............................................................................................................. 35 
 History of Device Modifications or Recall  .................................................................................... 36 
8 Requirements for Investigator Records and Reports  ........................................................................... 36 
 Deviations from CIP ..................................................................................................................... 36 
 Safety Reporting  .......................................................................................................................... 36 
8.2.1  Criteria and Guidelines for Reportable Events  ........................................................................ 37 
8.2.2  Criteria and Guidelines for Non- Reportable Events  ................................................................ 38 
8.2.3  Subject Death  .......................................................................................................................... 38 
8.2.4  UADEs  ..................................................................................................................................... 38 
 Source records  ............................................................................................................................ 38 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 4 of 71 
  
 Records Retention  ....................................................................................................................... 39 
9 Clinical Data Handling  .......................................................................................................................... 39 
 Protection of Personally Identifiable Information  ......................................................................... 39 
 Data Management Plan (DMP)  ................................................................................................... 39 
 Document and Data Control  ........................................................................................................ 39 
9.3.1  Traceability of Documents and Data  ....................................................................................... 39 
9.3.2  Recording Data  ........................................................................................................................ 39 
10 Monitoring ............................................................................................................................................. 40 
11 Compliance Statement  ......................................................................................................................... 40 
 Statement of Compliance  ............................................................................................................ 40 
 Quality Assurance Audits and Regulatory Inspections  ............................................................... 40 
 Repeated and Serious Non -Compliance  ..................................................................................... 40 
12 Suspension or Premature Termination of the Clinical Trial  ................................................................. 41 
13 Clinical Trial Conclusion  ....................................................................................................................... 41 
14 Publication Policy  ................................................................................................................................. 41 
15 Reporting Results on ClincalTrials.gov Website  .................................................................................. 42 
Appendix A: CIP Revisions  ......................................................................................................................... 43 
Appendix B: Acronyms  ................................................................................................................................ 44 
Appendix C: Definitions  ............................................................................................................................... 46 
Appendix D: Justification of NT -proBNP and BNP Thresholds  ................................................................... 48 
Appendix E: Guidance for Management of Hemodynamic Parameters  ..................................................... 51 
Appendix F: Measures to Ensure Enrollment into the Randomized Arm  .................................................... 53 
Appendix G: NT -proBNP and BNP Thresholds According to BMI  .............................................................. 54 
Appendix H: Body Mass Index Calculator  ................................................................................................... 55 
Appendix I: Subject -Reported Outcome Measures  ..................................................................................... 56 
Appendix J: Calculation of Glomerular Filtration Rate  ................................................................................ 57 
Appendix K: 6- Minute Hall Walk Test Instructions  ...................................................................................... 58 
Appendix L: Enrollment Flow Chart  ............................................................................................................. 59 
Appendix M: Randomized Arm Subject Contact Worksheet  ....................................................................... 60 
Appendix N: Single Arm Echocardiogram and Quality -of-Life Sub- Study  .................................................. 62 
Appendix O: CIP Summary  ......................................................................................................................... 63 
Appendix P: Bibliography  ............................................................................................................................ 69 
 
  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 5 of 71 
  
1 Introduction 
This document is a clinical investigation plan ( CIP) for the Hemodynamic -GUIDEd Management of  Heart 
Failure (GUIDE -HF) clinical trial. This clinical trial is intended to demonstrate the effectiveness of the 
CardioMEMS ™ HF System in patients with New York Heart Association (NYHA) Class II , III, or IV Heart 
Failure (HF) who have an elevated N -terminal pro-B rain Natriuretic Peptide ( NT-proBNP ) (or an elevated 
Brain Natriuretic Peptide (BNP) ) and/or a prior HF Hospitalization (HFH) . This clinical trial will be 
conducted under an investigational device exemption (IDE) and is intended to support an expanded indication for the CardioMEMS™ HF System. This clinical trial is sponsored by Abbott.  
 The clinical trial will be conducted in accordance with this CIP. All parties involved in the conduct of the 
clinical trial will be qualified by education, training, or experience to perform their tasks , and this training 
will be documented appropriately.  
2 B ackground and J ustification  for Clinical Trial  
HF affects over six  million Americans, with 960,000 new cases diagnosed each year . The syndrome 
tends to be progressive and is associated with severe morbidity and high mortality. H F costs the United 
States  healthcare system over $30 billion annually ( 1), with the largest cost component associated with 
over 1.2 million annual hospitalizations required to provide rescue therapy during acute decompensation of the chronic condition. H F is a growing pandemic with estimates from the American Heart Association 
(AHA) predicting the prevalence of HF in the United States to approach nine  million patients by 2030, with 
an associated increase to three million hospitalizations yearly. Innovative approaches focusing on 
decreasing decompensation events are needed to not only improve patient quality of life and survival, but 
also reduce the overall cost of delivering healthcare to HF patients  (1-3). Implantable hemodynamic 
monitoring systems are one such innovative approach that have been proven effective in maintaining 
stability in selected HF patients by providing a novel clinical disease management strategy that proactively avoids decompensation, replacing the traditional reactive rescue approach to treat acute 
decompensation. Remote pulmonary artery (PA) pressure monitoring provides clinical providers with 
actionable data to guide patient -centric individualized medication dosing and adjustments with the goal of 
preventing HFHs  or other decompensation events ( 4-7). The CardioMEMS ™ HF System is currently the 
only FDA approved system indicated for previously hospitalized NYHA Class III HF patients, regardless of left ventricular ejection fraction (LVEF), with the goal of  reduc ing HFHs . The system  is comprised of a 
lead-less, battery -less pressure sensor per manently implanted in the PA, which remotely transmits PA 
pressure measurements from the patient’s home to a secure website. Healthcare professionals are able 
to access these measurements and associated waveforms to remotely guide individualization of medical 
management  for their patients with chronic HF . The purpose of the GUIDE- HF clinical trial is to discover 
whether hemodynamic -guided HF management is applicable to a larger group of at -risk HF patients and 
whether maintaining hemodynamic stability improves overall survival and quality -of-life in such HF  
patients.  
2.1.1  CardioMEMS™ Clinical Experience  
The safety and effectiveness of the CardioMEMS ™ HF System was evaluated in the CHAMPION 
(CardioMEMS ™ HF Sensor Allows Monitoring of Pressures to Improve O utcomes in N YHA Functional 
Class III HF Patients) trial ( ClinicalT rials.gov Identifier: [STUDY_ID_REMOVED]). CHAMPION was a prospective, 
multi -center, randomized, controlled trial, which demonstrated a significant reduction in HFHs when PA 
pressure measured by  the CardioMEMS ™ PA Sensor  was used by clinician s to guide HF patient 
management  (Treatment Group), compared to patients managed without clinician  knowledge of PA 
pressure information (Control Group) ( 5, 8). This included the first treatment strategy to successfully 
improve outcomes in HF patients with a preserved ejection fraction ( EF) (HFpEF) ( 9). Additionally, 
hemodynamic -guided HF care in patients with reduced HF (HFrEF) augmented the survival benefit of 
guideline directed medical therapy  (GDMT) ( 10, 11). Results of the CHAMPION trial led to the Food and 
Drug Administration (FDA) approval of the CardioMEMS ™ HF System for wirelessly measuring PA 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 6 of 71 
  
pressure to guide HF management  in NYHA Class III HF patients who experienced a HFH in the previous 
year.   
 Early experience with the CardioMEMS ™ HF System in a post-FDA approval,  real-world environment 
continues to support the utility of hemodynamic -guided HF management  for this population. In particular, 
PA pressure- guided HF management  using the implantable CardioMEMS ™ PA Sensor in large real -
world cohorts demonstrated reduced HFHs ( 12), along with a concomitant reduction in PA pressure ( 13). 
Real-world reductions in HFH s were associated with significant cost savings based on Medicare claims 
data. Additional clinical evidence on post -market experience with CardioMEMS™ in this population is 
currently being generated in a post -approval registry study (PAS,  [STUDY_ID_REMOVED]) in 1,200 patients 
followed for two  years . Enrollment in this registry was completed earlier than expected and is currently in 
the long- term follow -up phase . Preliminary results in the first 300 patients followed for at least six  months 
found a lower HF H rate c ompared to the CHAMPION Trial Treatment G roup, despite the fact that the 
PAS population is older with more advanced HF syndromes  (14, 15).  
2.1.2  Patient Selection for CardioMEMS ™ Therapy  
The CardioMEMS ™ HF System is currently indicated for use in NYHA Class III HF  patients, who have a 
documented HFH in the prior year.  However, determination of these prerequisite conditions for patient 
selection can be challenging. The NYHA classification of HF symptoms is designed to subjectively 
quantify an individual’s burden of congestive symptoms in order to provide specific medical and device interventions appropriate for the patient’s condition. Accurate assessment of NYHA Class is limited by 
several important factors including the tendency for patients to accommodate chronic symptoms and variability in healthcare providers’ diligence in historical assessment . These limitations may lead to 
misclassification of HF patient status , leading to a missed opportunity for preventive care. Biomarker 
assessment of HF patient status, particularly utilizing B -Type Natriuretic Proteins (NT -proBNP or BNP) 
may provide a superior means to determine the presence of subclinical congestion, thus providing a 
better prognos tic assessment of the patient’s subsequent risk for decompensation  than NYHA class . 
Furthermore, it is now clear that U nited States  clinical management trends have shifted away from 
hospitalization to treat acutely decompensated HF (ADHF)  to increased reliance on outpatient 
intravenous medication intervention. However,  regardless of the venue, decompensation requiring rescue 
therapy is associated with increased long- term mortality risk . Therefore, it is plausible to hypothesize that 
hemodynamic -guided care may be appropriate for patients whose clinical congestion status is determined 
by NT-proBNP (or BNP) even when clinical symptoms are assessed as NYHA Class II, III, or IV  HF. 
Given the prognostic value of elevated NT -proBNP (or BNP) , patients without history of a previous HFH 
may also benefit from  hemodynamic -guided HF management strategies.  
2.1.3  Natriuretic Peptides in HF 
Natriuretic peptides, specifically NT -proBNP and BNP , are released into the circulation directly from the 
myocardium due to increased end- diastolic wall stress as a result of increased end diastolic volume and 
pressure ( 16). Natriuretic peptides are most commonly used to support the diagnosis of HF in patients 
with dyspnea, and numerous studies have demonstrated that NT -proBNP and BNP  are strong 
independent predictors of adverse clinical outcome in HF patients ( 17). In the Breathing Not Properly 
study, a BNP threshold of 100 pg/ml accurately diagnosed acute HF with a sensitivity of 90% and a specificity of 76% ( 18). In the COMET study, a progressively increasing risk for mortality was observed 
with every 10% increase in NT -proBNP  (19). The Agency for Healthcare Research and Quality of the 
Department of Health and Human Services in 2006 assessed 58 studies where NT -proBNP  or BNP  were 
evaluated in predicting cardiac events in primarily NYHA Class II , III or IV HF patients ( 20). A majority of 
the studies found baseline NT-proBNP  or BNP  to be independent predictors of mortality. This makes NT -
proBNP and/or BNP a ssessment s a promising alternative to prior HFHs for objectively identifying patients 
who are at high risk for HFHs and mortality, and who may derive clinical benefits from PA pressure-guided HF management  (for more details see  Appendix D ). These data have supported a Class I 
recommendation for measurement of NT -proBNP or BNP to establish prognosis or disease severity in 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 7 of 71 
  
chronic HF ( 21) and have resulted in NT -proBNP and BNP assessment being included as an entry 
criterion for numerous clinical trials in HF such as LAPTOP -HF (trial of a device for hemodynamic 
monitoring, [STUDY_ID_REMOVED] ( 7)), PARADIGM -HF and PARAGON -HF (trials of s acubitril- valsartan in HFrEF 
and HFpEF patients, [STUDY_ID_REMOVED]  (22, 23), [STUDY_ID_REMOVED] ( 24)), and COAPT (trial of MitraC lip 
percutaneous repair for  functional mitral regurgitation, [STUDY_ID_REMOVED]).  
2.1.4  Clinical Trial Rationale  
These data support the hypothesis that hemodynamic -guided HF management using the CardioMEMS ™ 
HF System  may be effective in a NYHA Class II , III, or IV HF patient population with elevated NT -proBNP 
(or BNP) . Furthermore, the utility of elevated NT -proBNP (or BNP)  and its equivalence to a history of 
previous HFHs for appropriate selection of HF patients  for CardioMEMS ™ implantation is plausible, but 
currently unknown. Hence, t he rationale for conducting this clinical trial is two -fold: 
 
• To generate scientific evidence supporting the clinical benefit of PA pressure- guided HF 
management  in a broad range of HF patients  (NYHA Class II , III, or IV) , reflecting contemporary 
methods of patient selection (elevated NT-proBNP (or BNP) ) 
• To demonstrate the equivalence of elevated NT -proBNP (or BNP) to prior HFHs for selecting the 
appropriate candidates who will clinically benefit from PA pressure- guided HF management, and 
to allow for the expansion of the current label  to include NYHA Class III HF patients with elevated 
NT-proBNP (or BNP)  
 This clinical trial proposes to build on the clinical experience gained from the CHAMPION trial  and 
attempts to fill an important clinical evidence gap in the management of eligible HF patients (including 
Medicare beneficiaries). The Sponsor  is proposing to conduct an IDE trial to obtain pre- market approval 
(PMA) of the CardioMEMS ™ HF System for NYHA Class II , III, or IV HF patients who have experienced 
either a HFH within the last 12 months (“prior HFH”) or have elevated NT -proBNP (defined as ≥ 1000 
pg/mL for LVEF ≤ 40%  or ≥ 700 pg/mL for LVEF > 40% ) (or elevated BNP, defined as ≥ 250 pg/mL for 
LVEF  ≤ 40%  or ≥175 pg/mL for LVEF > 40% ) within the last 30 days.  Thresholds for NT -proBNP and 
BNP (for both LVEF ≤ 40% and LVEF > 40%) will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m
2 (23), see Appendix G  for NT -proBNP (and BNP) thresholds 
according to BMI . 
3 Device(s) Under Investigation  
 Identification and Description of the Devices under I nvestigation  
3.1.1  Identification  
Table  1 details the devices to be used in this trial. Although market released, the CardioMEMS™ HF 
System is not FDA approved for the proposed clinical trial population (NYHA Class II , III, or IV HF 
patients with elevated NT -proBNP (or BNP)). 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 11 of 71 
  
complete baseline assessments. Within 60 days of consent, subjects will receive a CardioMEMS ™ HF 
System . Subjects will be considered enrolled in the Single Arm once all entry criteria are met, informed 
consent is provided, and implantation of the CardioMEMS ™ PA S ensor is attempted.  Safety information 
and adverse events (AEs) will be reported (per section 8.2) for all enrolled subjects.  However, subjects 
will only contribute towards the sample size and primary, secondary effectiveness, and descriptive 
endpoint  analyses following successful implantation. Subjects will  upload PA pressure information daily, 
and receive HF management guided by PA pressure information.  
 The GUIDE -HF Single Arm  will include approximately 2600 subjects  (following successful implantation)  at 
approximately 140 sites. Each subject will be followed for 12 months, with follow -up visits  at 6 and 12 
months . 
 Objectives  
GUIDE -HF Randomized Arm : The objective of the GUIDE- HF Randomized Arm  is to determine if PA 
pressure- guided HF management  using CardioMEMS ™ improves health outcomes in NYHA Class II , III, 
or IV  HF patients  with either elevated NT -proBNP (or BNP)  and/or a prior HFH.  
 GUIDE -HF Single Arm : The objective of the GUIDE- HF Single Arm is to demonstrate the equivalence of 
the effect of PA pressure- guided HF management on health outcomes between NYHA Class III HF 
patients with elevated NT -proBNP  (or BNP)  only and those with a prior HFH  only. 
 Endpoints  
Refer to Appendix C  for event definitions used for the trial endpoints . 
4.3.1  GUIDE -HF Randomized Arm  
The GUIDE -HF Randomized Arm will eva luate one primary endpoint, several secondary endpoints, and 
several descriptive endpoints.  All endpoints will be compared between the Treatment and Control Groups  
unless otherwise noted .  
4.3.1.1  Primary Endpoint  
The primary endpoint is a composite of recurrent HFHs or emergency department /hospital outpatient 
observation visits for intravenous  diuretic therapy or all -cause mortality at 12 months  post-implantation 
(referred to as the Composite Endpoint ). Emergency department visits and hospital outpatient 
observation visits involving intravenous diuretics, along with HFHs, are included in the primary endpoint, 
as the duration of hospitalization can vary , and decompensation events requiring intravenous diuretic 
therapy impact subject  quality -of-life and mortality , regardless of form (inpatient or outpatient) . The 
following events will be included in the composite: 1 ) hospitalization (≥ 24 hours)  with the primary reason 
for admission  being  acute decompensated HF and intravenous  administration of diuretic therapy ; 2) an 
unscheduled or unplanned admission to the emergency department , hospital outpatient observation visit , 
or hospital inpatient visit  and intravenous  administration of diuretic  therapy ; 3) all -cause mortality . All 
events contributing to the primary endpoint  will be adjudicated by an independent  Clinical Events 
Committee ( CEC ) (see section 5.10.4 for details) . In rare instances, CEC discretion may be used to 
determine whether additional criteria would identify  a decompensation event that c ould represent a valid 
contribution to the primary endpoint (e.g., ultra- filtration in lieu of diuretics).  
4.3.1.2  Secondary Endpoints  
The s econdary effectiveness endpoints are: 
• Composite of recurrent HFHs or emergency department/hospital outpatient observation visits for 
intravenous diuretic therapy  
• Health status at baseline, 6, and 12 months post -implantation as assessed by the EuroQol 5-
Dimension, 5- Level ( EQ-5D-5L) Questionnaire  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 12 of 71 
  
• Health status at baseline, 6, and 12 months post -implantation as assessed by the Kansas City 
Cardiomyopathy Questionnaire (KCCQ -12) 
• Six Minute Hall Walk (6MHW) test at baseline, 6, and 12 months post-implantation 
• In addition, the individual  components of the primary endpoint will each be evaluated as 
descriptive secondary effectiveness endpoints : 
o HFHs at 12 months post -implantation  
o Emergency department/hospital outpatient observation visits for intravenous diuretic therapy at 12 months post -implantation  
o All-cause mortality at 12 months post -implantation  
 The secondary safety endpoint is freedom from device/system related complications (DSRCs) at 12 months post -implantation. The secondary safety endpoint will be evaluated for all subjects enrolled in the 
Randomized Arm (i.e. with an attempted implant, whether successful or unsuccessful) and reported for the entire subject cohort  and by subject group. 
4.3.1.3  Descriptive Endpoints  
Descriptive endpoints are reported using only summary statistics and no hypothesis tests will be performed.  All mortality - and hospitalization- related components of the primary endpoints will be 
adjudicated by the CEC. The following additional data will be collected and reported: 
• Cardiovascular mortality at 12 months  post-implantation 
• All-cause hospitalizations at 12 months  post-implantation  
• Frequency of subject  PA pressure uploads  through 12 months  
• HF medication changes through  12 months  
• PA pressure measurements from baseline through 12 months  
• NT-proBNP  (or BNP ) at baseline, 6, and 12 months  
• HFHs at 12 months  post-implantation compared to HFHs in the 12 months prior to implantation  
4.3.2  GUIDE -HF Single Arm  
The GUIDE -HF Single Arm  will evaluate  one primary endpoint , several  secondary endpoint s, and several  
descriptive endpoints.  
4.3.2.1  Primary Endpoint  
The primary endpoint is a composite of recurrent  HFHs or  emergency department /hospital outpatient 
observation visits for intravenous  diuretic therapy or all -cause mortality at 12 months  post-implantation 
(same as for the Randomized Arm) , to be compared between subjects with an elevated NT -proBNP (or 
BNP)  only and subjects with a prior HFH only. Subjects who have both elevated NT -proBNP (or BNP)  
and a prior HFH will not be included in the analysis for the primary endpoint. All events contributing to the 
primary endpoint will be adjudicated by the CEC  (see section 5.10.4 for details) . In rare instances, CEC 
discretion may be used to determine whether additional criteria would identify a decompensation event that could represent a valid contribution to the primary endpoint (e.g., ultra- filtration in lieu of diuretics).  
4.3.2.2  Secondary Endpoint s 
The secondary  effectiveness  endpoint s are:  
• Composite of recurrent HFHs or emergency department/hospital outpatient observation visits for 
intravenous diuretic therapy  at 12 months post -implantation  
• HFHs at 12 months  post-implantation compared to HFHs in the 12 months prior to implantation. 
All subjects who receive a CardioMEMS ™ PA Sensor  implant will be included in the analysis of 
this endpoint.  
• In addition, the individual components of the primary endpoint will each be evaluated as 
descriptive secondary effectiveness endpoints:  
o HFHs at 12 months post -implantation  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 13 of 71 
  
o Emergency department/hospital outpatient observation visits for intravenous diuretic therapy at 12 months post -implantation  
o All-cause mortality at 12 months post -implantation  
 The secondary safety endpoint is  freedom from DSRCs at  12 months post -implantation. The secondary 
safety endpoint will be evaluated for all subjects enrolled in the Single Arm (i.e. with an attempted implant, whether successful or unsuccessful) and reported for the entire subject cohort and by subject group.  
4.3.2.3  Descriptive Endpoints  
Descriptive endpoints are reported using only summary statistics and no hypothesis tests will be performed.  All mortality - and hospitalization- related components of the primary endpoints will be 
adjudicated by the CEC. The  following additional data  will be collected and analyzed. The EQ -5D-5L, 
KCCQ -12, and 6MHW test will be collected and reported only for the first 1000 subjects enrolled and 
successfully implanted in the Single Arm.  
• Health status at baseline, 6, and 12 months post -implantation as assessed by EQ-5D-5L 
• Health status at baseline, 6, and 12 months post -implantation as assessed by the KCCQ -12 
• 6MHW  test at baseline, 6, and 12 months post -implantation  
• Cardiovascular mortality at 12 months  post-implantation 
• All-cause hospitalizations at 12 months  post-implantation  
• Frequency of subject PA pressure uploads  through 12 months  
• HF medication changes  through  12 months  
• PA pressure measurements from baseline through 12 months  
• NT-proBNP  (or BNP ) at baseline, 6 months, and 12 months  
 Clinical Trial Population 
The intended population for this clinical trial includes  patients over the age of 18 years with symptomatic 
NYHA class II , III, or IV HF and either a prior HFH within the past 12 months and/ or elevated NT -proBNP 
(or BNP)  within 30 days prior to consent , that meet the trial  entry criteria defined below . Refer to Appendix 
C for NYHA class definitions.  
4.4.1  Inclusion Criteria  
To participate in this clinical trial  and receive a CardioMEMS ™ HF System implant, subjects must meet 
all of the following inclusion criteria:  
1. Diagnosis and treatment for HF  (regardless of LVEF)  for > 90 days prior to the date of consent:  
a. Subjects should  be on stable, optimally titrated medical therapy for at least 30 days, as 
recommended according to current AHA/ American College of Cardiology (ACC) 
guidelines as standard- of-care for HF therapy in the United States, with any intolerance 
documented.  
2. GUIDE -HF Randomized Arm  Only : NYHA Class II , III or IV HF symptoms documented within 30 
days prior to consent.  
3. GUIDE -HF Single Arm Only: NYHA Class III HF symptoms documented within 30 days prior to 
consent.  
4. HFH within 12  months prior to consent and/ or elevated NT -proBNP (or BNP) within 30 days prior  
to consent  defined as:  
a. Subjects with LVEF ≤ 40% : NT-proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL). 
b. Subjects  with LVEF > 40% : NT-proBNP ≥ 700 pg/mL (or BNP ≥  175 pg/mL). 
c. Thresholds for NT -proBNP and BNP (for both LVEF ≤ 40%  and LVEF  > 40%) will be 
corrected for BMI using a 4% reduction per BMI unit over 25 kg/m2  
5. ≥ 18 years of age 
6. Chest circumference of < 65 inches, if BMI is > 35 kg/m2 
7. Written informed consent obtained from subject  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 14 of 71 
  
8. Willing and able to upload PA pressure information and comply with the follow -up requirements  
4.4.2  Exclusion Criteria  
Subjects who meet any of the following criteria must be excluded from the clinical trial : 
1. Intolerance to all neuro- hormonal antagonists ( i.e., intolerance to angiotensin converting e nzyme-
inhibitors (ACE -I), angiotensin receptor b lockers (ARB), a ngiotensin-n eprilysin inhibitor s (ARNi) , 
hydralazine/isosorbide dinitrate and beta-b lockers)  
2. ACC/AHA Stage D refractory HF  (including having received or currently receiving pharmacologic 
circulatory support with inotropes)  
3. Received or are likely to receive an advanced therapy (e.g., mechanical circulatory supp ort or 
cardiac transplant) in the next 12 months  
4. NYHA Class IV HF patients  with: 
a. Continuous or chronic use of scheduled intermittent inotropic therapy for HF and an INTERMACS level of ≤  4, OR 
b. Persistence of fluid overload  with maximum (or dose equivalent) diuretic intervention  
5. Glomerular Filtration Rate (eGFR)  < 25 mL/min/1.73m
2 and non-responsive to diuretic therapy, or 
receiving chronic dialysis  
6. Inability to tolerate  or receive dual antiplatelet therapy or anticoagulation therapy for one month 
post-implantation  
7. Significant congenital heart disease that has not been repaired and would prevent implantation of 
the CardioMEMS ™ PA Sensor  
8. Implanted with mechanical right heart valve(s)  
9. Unrepaired severe valvular disease  
10. Pregnant or planning to become pregnant in the next 12 months  
11. An active, ongoing  infection , defined as being febrile, an elevated white blood cell count, on 
intravenous  antibiotics, and/or positive cultures (blood, sputum or urine).  
12. History of current or recurrent ( ≥ 2 episodes within 5 years prior to consent ) pulmonary emboli  
and/or deep vein thromboses  
13. Major cardiovascular event (e.g., unstable angina, myocardial infarction, percutaneous coronary 
intervention, open heart surgery, or stroke, etc.) within 90 days prior to consent  
14. Implanted with Cardiac Resynchronization Therapy (CRT) -Pacemaker ( CRT-P) or CRT -
Defibrillator (CRT -D) for less than 90 days  prior to consent  
15. Enrollment into another trial with an active treatment arm 
16. Anticipated life expectancy of < 12 months  
17. Any condition that , in the opinion of the Investigator,  would not allow for  utilization of the 
CardioMEMS ™ HF System to manage the subject using information gained from hemodynamic 
measurements  to adjust medications , including  the presence of unexpectedly severe pulmonary 
hypertension (e.g. , trans -pulmonary gradient >15) at implant RHC , a history of non -compliance, 
or any condition that would preclude CardioMEMS ™ PA Sensor implantation  
4.4.3  Enrollment of Medicare Beneficiaries  
This clinical trial will enroll appropriate Medicare beneficiaries that qualify based on the inclusion and 
exclusion criteria set forth in the trial. Th is IDE clinical trial adheres to all standards of Medicare coverage 
requirements set forth by the IDE and clinical trial coverage policies  of the Center for Medicare and 
Medicare Services  (CMS ). Section 7, Risks and Benefits , describes how all enrolled subject s, including 
Medicare beneficiaries, may be affected by the CardioMEMS ™ HF System  under investigation.  
 Subjects enrolled in the clinical trial  are expected to be consistent with the Medicare population based on 
demographic characteristics and cardiovascular risk factors; therefore, the clinical trial results are 
expected to be generalizable to the Medicare population.  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 18 of 71 
  
 
 Subject  Recruitment  
For the recruitment of subjects, sites will screen charts from their own HF patient population and/or reach 
out to clinician s within t heir referral base. Any subject -facing recruitment materials or advertisements will 
require both Sponsor  and IRB approval prior to use.  
 Point of Enrollment  
In both the Randomized Arm and Single Arm, subjects will be considered enrolled once all entry criteria are met, informed consent is provided, and implantation of the CardioMEMS ™ PA Sensor is attempted. 
Safety information and adverse events (AEs) will be reported (per section 8.2) for all enrolled subjects . 
However, subjects will only contribute towards the sample size and all other endpoint analyses following 
successful implantation and randomization (Randomized Arm) or following successful implantation (Single Arm) . See Appendix L  for a flow chart reflecting trial enrollment procedures.  Subjects who provide 
written informed c onsent , but fail to meet entry criteria (or choose to no longer participate) prior to an 
attempted implantation will be considered screening failures. Subjects with an attempted, but unsuccessful , implant  will be followed for 30  days post -implant ation  attempt  for safety and/or will undergo 
a re-attempted implantation procedure (see s ection 5.4.4.1 for details).   
 The Principal Investigator or delegated trial  personnel will record enrollment information ( including, but 
not limited to  the date of implant (Single Arm), date of consent , and inclusion/exclusion information) in the 
subject  records and complete and submit the applicable CRF s. Notification of enrollment to the Sponsor 
is considered to have occurred when the Sponsor has received documentation of the enrollment information via the applicable CRF s. 
 Scheduled Procedures  
The Principal Investigator is responsible for ensuring all clinical trial data are collected as required per this 
CIP. 
 Trained Sponsor personnel may provide technical expertise and technical guidance on the use of the CardioMEMS ™ HF S ystem, including the Merlin.net ™ website, implant training and proctoring for 
implantations for sites using the CardioMEMS ™ HF System  for the first time.  
5.4.1  Screening Procedures   
The following information will be evaluated from medical records and documented, to ensure each subject meets entry criteria prior to consent. Subjects are required to have either a HFH within the previous 12 months or a documented elevated NT -proBNP (or BNP) within the previous 30 days (outside of clinical 
trial procedures  per standard- of-care). Documentation of a prior HFH and/or elevated NT -proBNP (or 
BNP) is required for verification of inclusion  and exclusion criteria. If necessary, screening procedures to 
address other entry criteria (such as EF and e GFR, if not previously documented) can be evaluated 
during the baseline visit following consent .  
• Duration of HF from first diagnosis  
• NYHA class evaluation within the previous 30 days  
• All HFH s within the previous  one year, as  provided by the subject ’s cardiologist, internist, or 
referring physicians  including gathering of source documentation of hospitalizations  
• Laboratory analyses for qualifying NT-proBNP  (or BNP) within the previous 30 days  for inclusion 
verification  (outside of clinical trial procedures)  
• EF within six  months prior to the consent date (can be from echo, nuclear testing, angiography, 
CT, MRI). If no documentation exist s in the required timeframe, a limited echo to document EF 
only will be required during the baseline visit . 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 19 of 71 
  
• Calculation of BMI using subject height and weight (see Appendix H) and calculation of chest 
circumference measurement if BMI > 35kg/m2 
• Age 
• Cardiovascular history includ ing: 
o previous cardiac procedures and CRT device information  
o relevant co- morbidities  
• HF medication review with documentation  
5.4.2  Informed Consent  
As this IDE trial has two distinctly unique arms  (Randomized Arm and Single Arm), one of two Informed 
Consent Forms will be utilized detailing requirements and considerations in each arm. The Principal Investigator or his/her authorized designee will conduct the informed c onsent p rocess, as required by 
applicable regulations and the center’s IRB/EC. This process will include a verbal discussion with the subject on all aspects of the clinical trial that are relevant to the subject’s decision to participate such as 
details of the procedures, anticipated benefits, and potential risks of clinical trial participation. During the 
discussion, the Principal Investigator or his/her authorized designee will avoid any improper influence on the subject and will respect the subject’s legal rights. The subject shall be provided with the I nformed 
Consent F orm (for the applicable trial arm) written in a language that is understandable to the subject and 
has been approved by the center’s IRB/EC. The subject shall have adequate time to review, ask questions and consider participation.  
 If the subject agrees to participate, the Informed Consent F orm for the applicable trial  arm must be signed 
and dated by the subject  and by the person obtaining the consent. The signed original will be filed in the 
subject’s hospital or research charts, and a copy will be provided to the subject.  
 The Principal Investigator or his/her authorized designee will document the informed consent process in the subject’s hospital and/or research charts. The date of signature will be entered on the applicable  CRF. 
 Failure to obtain informed consent from a subject prior to clinical trial enrollment should be reported to 
Sponsor within five  working days and to the reviewing center’s IRB/EC according to the IRB’s/ EC’s 
reporting requirements.  
 If, during the clinical trial, new information becomes available that can significantly affect a subject's health and medical care, the Principal Investigator or his/her authorized designee will provide this information to the subject. If relevant, the subject will be asked to confirm their continuing informed 
consent in writing.  
5.4.3  Baseline Procedures  
The following assessments and information will be collected during the baseline visit prior to implant (see 
Table 2 for additional details).  The Quality of Life assessments (KCCQ -12 and EQ -5D-5L) should be 
administered prior to all other baseline procedures.  
• KCCQ -12 Quality of Life assessment  (see Appendix I for details)  
• EQ-5D-5L Quality of Life assessment  (see Appendix I  for details)  
• Verification of inclusion and exclusion criteria (as necessary from the screening procedures)  
• Documentation of key demographic information such as ethnicity, gender and age 
• Cardiovascular h istory  including : 
o previous cardiac procedures and CRT device information  
o relevant co- morbidities  
• HF assessment including NYHA class evaluation  
• HF medication review with documentation  
• Laboratory analyses for baseline NT-proBNP (or BNP)  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 26 of 71 
  
• Medication review and documentation  
 Clinical Trial Committees  
5.10.1  Steering C ommittee  
A Steering Committee has been formed to advise the Sponsor on key aspects related to the 
development, execution, analysis and reporting, and overall conduct of the clinical trial. The primary 
function, responsibilities and membership of the Steering Committee will be described in detail in a 
Steering Committee  charter.  
5.10.2  Publication Committee  
A Publication Committee shall be established to oversee trial  publications, including publication planning 
and authorship determinations. Publication Committee membership may include members of the Steering Committee, Principal Investigators, a representative of the Sponsor and a statistician. The primary function, responsibilities and membership of the Publication Committee, as well as rules to define authorship,  will be described in detail in a Publication Committee charter.  
5.10.3  Data Safety Monitoring Board  (DSMB) 
An independent DSMB will review on a regular basis accumulating data from the clinical trial and will 
advise the Sponsor regarding the continuing safety of subjects and those yet to be recruited, as well as the continuing validity and scientific merit of the clinical trial. However, analysis of efficacy will not be used 
by the DSMB to consider continuance of the trial . DSMB  members will not be Investigator s in the clinical 
trial. At any time during the investigation, the DSMB  may offer opinions or provide formal 
recommendations concerning aspects of the trial  that impact subject safety (e.g.  safety -related prot ocol 
changes or input regarding CardioMEMS ™ HF System -related A E rates) . The function, responsibi lities 
and membership of the DSMB  will be described in detail in a DSMB charter . 
5.10.4  CEC  
A CEC will be responsible for providing an independent review and adjudication of  the following data:  
• Events that could contribut e to primary endpoints for either trial arm, to determine which events 
meet primary endpoint qualification, including:  
o All cardiovascular hospitalizations, cardiovascular emergency department visits,  and 
cardiovascular hospital outpatient visits , all defined as a hospital visit with the primary 
cause being cardiovascular in nature, as  reported by the Investigator  
o All deaths  
o Any hospitalizations which, when reviewed by the Sponsor , could potentially  meet 
endpoint qualification  
• HFHs that occurred within 12 months  prior to baseline  
• All events that could contribute to the secondary safety endpoint for either trial arm including ADEs , SADEs, and UADEs  
 All attempts will be made to blind the CEC  to the treatment group assignment . The function, 
responsibilities and membership of the CEC will be described in greater detail in a CEC charter.   
6 Statistical Considerations  
The following section describes the statistical methods for the clinical trial and justification of the design. 
Additional details on statistical analyses, including sensitivity analyses, poolability analyses, subgroup analyses and analysis of descriptive endpoint(s) will be described in a separate Statistical Analysis Plan 
(SAP).  Hypothesis tests will be 1- sided and conducted at a significance level of 2.5% unless stated 
otherwise.  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 34 of 71 
  
• Bleeding  
o Epistaxis  
o Hemoptysis  
o GI bleed  
o Bleeding  
o Blood in stool  
o Catheter site bleeding  
o Catheter site ecchymosis  
o Hematuria  
o Nose bleeds  
• Hematoma  
o Hematoma  
o Catheter site hematoma  
o Vessel puncture site hematoma  
• Thrombus  
o Arterial thrombosis (limbs)  
o Blood clot  
• Myocardial infarction  
• Transient ischemic attack  
• Stroke  
• Death  
• Sensor  embolization  
• Pulmonary artery perforation 
 
Refer to the CardioMEMS ™ PA Sensor and Delivery Catheter, Model CM2000 User Manual for more 
information. If there are any questions regarding whether an event meets the associated definition (see 
Appendix C ), the in- house Sponsor  contact should be consulted.  
7.1.2  Anticipated ADEs/SADEs  
The following is a list of possible anticipated ADE s/SADEs:  
• Hemoptysis  
• Sensor  not deploying  
• Transient ischemic attack  
• Atypical chest pain  
• Sepsis leading to death  
• Atrial arrhythmia leading to death  
• Arterial embolism (upper extremity)  
• PA (in-situ) thrombus  
• Catheter site bleeding  
• Catheter site ecchymosi s 
• Catheter site hematoma  
• Vessel puncture site pain  
• Cardiac monitoring abnormal  
• Heart rate irregular  
• Serum creatinine increased  
• Dyspnea  
• Congestive HF  
• Ventricular tachycardia  
• Dizziness  
• Vessel perforation  
• Sensor failure/malfunction  
• Sensor migration  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 35 of 71 
  
• System not transmitting  
7.1.3  Non-AE Device Issue  
To adequately capture non- AE device issues, any device issues that fall outside of the AE definition (see 
Appendix C ), a separate form will be used to capture such instances when the device fails to perform or 
does not function properly without an associated an adverse clinical outcome.  
 Risk Control Measures  
Every possible effort will be taken to minimize the risks, including:  
• Careful selection of experienced Investigator s for the clinical trial   
• Early (within 60 days of the first enrollment) and adequate monitoring for each clinical trial site per 
the trial monitoring plan  
• Conducting the clinical trial in accordance with the CIP, all applicable laws and regulations  and 
any conditions of approval imposed by the appropriate IRB/EC or applicable regulatory authorities where the clinical trial is performed  
• Preparation of the CardioMEMS ™ PA Sensor  and performance of the implantation procedure in 
accordance with the IFUs 
• Training of Investigator s both on the CIP and the CardioMEMS ™ PA Sensor  implantation 
procedure  
• Securing compliance of non- compliant sites (see section 11.3)  
• Assessment of continuing safety of subjects in the clinical trial by a DSMB  
 Possible interactions with concomitant treatments  
The CardioMEMS ™ PA Sensor  is implanted in the PA via entry through the right side of the heart. If other 
device right heart leads are previously implanted, it is possible to cause dislodgement. Care should be taken to perform the implant procedure under fluoroscopy.  
 Anticipated Benefits  
The benefit of hemodynamic -guided HF management  in this population is unknown and information will 
be learned from this trial. Subject s with NYHA Class III HF and a prior HFH studied in the  Treatment 
Group of the CHAMPION ™ trial experienced a reduction in HF  admissions. However, there is no 
guarantee that a similar benefit will occur in this slightly different population of NYHA Class II , III, or IV HF 
patients with a prior HFH and/or elevated NT-proBNP  (or BNP) . The information gathered will provide 
additional evidence regarding hemodynamic -guided HF management  in at-risk NYHA Class II, III, or IV  
HF patients.  
 Risk -to-Benefit R ationale  
Congestive HF  is a progressive disease and HF patients are generally symptomatic. Symptoms of 
dyspnea and fatigue increase with elevations of pressures within the heart and lungs, leading to instances of acute HF decompensation. The CardioMEMS ™ HF System enables clinicians to medically manage HF 
patients by adjusting treatments to keep PA pressures within target ranges to prevent or reduce instances 
of acute HF decompensation. In doing so, the CHAMPION ™ trial demonstrated a reduction in rates  of HF 
decompensation resulting in an HFH  in NYHA Class III patients who had a HFH within the prior 12 
months . Treating with the knowledge of PA pressures may extend benefit to this at -risk population of HF 
patients with the goal of reduc ing decompensation events that result in HFHs or emergency 
department/hospital outpatient visits requiring intravenous  diuretic therapy. The trial is designed to 
demonstrate this benefit to an expanded patient population. 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 36 of 71 
  
 History of Device Modifications or Recall  
There have been no modifications or recall in relation to safety and clinical performance of the CardioMEMS ™ HF System  under investigation. 
8 Requirements for Investigator Records and R eports  
 Deviations from CIP  
A deviation is defined as an instance of failure to follow, intentionally or unintentionally, the requirements of the CIP. The Investigator  should make every effort not  to deviate from the CIP, and all deviations must be 
reported .  
 If a subject is successfully implanted and/or  randomized, but later found to not meet all inclusion/exclusion 
criteria, the subject will remain enrolled and a protocol deviation must be submitted.  
 Additionally,  in the event that the IFU is not followed and an alternative implantation approach is pursued, 
the alternative implantation approach and associated justification must be reported as a protocol deviation.  The Sponsor will review and track deviation frequency and trends. All effort should be made to 
avoid deviations , and repeat offense will result in S ponsor intervention (see section 11.3). Deviations are 
expected to be infrequent.  
 In some cases, failure to comply with the CIP may be considered failure to protect the rights, safety and well-being of subjects; such non- compliance exposes subjects to unreasonable risks. Examples  include 
failure to comply with prescribed clinical trial procedures with respect to: obtaining ICF properly, 
performing assessments within the applicable time period, following the CardioMEMS ™ PA Sensor  
implantation procedure, following treatment guidelines (without documentation of the reason) , following 
subjec t contact procedures  (for the Randomized Arm) , adher ing to the inclusion/exclusion criteria,  and 
reporting device- related AEs. Investigators should seek to minimize such risks by adhering to the CIP.  
 The PI must maintain accurate, complete, and current records, including documents showing the date of and reason for each deviation from the CIP. Relevant information for each deviation will be documented as soon as possible on the applicable  CRF, and submitted by the site  to the Sponsor . 
 The PI is required to adhere to local regulatory requirements for reporting deviations to IRB/EC.  
 An Investigator  shall notify the Sponsor and the reviewing IRB/EC  of any deviation from the 
investigational plan to protect the life or physical well -being of a subject in an emergency. Such notice 
shall be given as soon as possible, but no later than five  working days after the emergency occurred. 
Except in such an emergency, prior approval by the Sponsor is required for changes in or deviations from the CIP, and if these changes or deviations may affect the scientific soundness of the CIP  or the rights, 
safety, or welfare of human subjects, FDA and IRB /EC is also requi red. 
 Safety Reporting  
Safety surveillance and the safety reporting by the Investigator  starts as soon as the subject is enrolled 
(all entry criteria are met, informed consent is provided, and implantation of the CardioMEMS ™ PA 
Sensor is attempted) in either the Randomized Arm or the Single Arm.   
 Safety surveillance and safety reporting will continue until the last investigational visit has been 
performed, the subject is deceased, the subject’s participation in the clinical trial is concluded by the 
Investigator,  or the subject withdraw s from the clinical trial. 
 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 37 of 71 
  
All reportable (per section 8.2.1)  AE data including deaths will be collected throughout the clinical trial and 
will be reported to the Sponsor on the applicable CRFs. 
 Reportable AE s will be monitored until they are adequately resolved or the subject has ended his/her 
participation in the trial, whichever comes first. The status of the subject’s condition will be  documented at 
each visit.  
 
See Appendix C  for event definitions regarding s afety reporting.  
 SAE Reporting  
 The investigator should report all SAEs to the Sponsor as soon as possible but no later than outlined below.  
 
Clinical Site  Reporting timelines  
All Sites  SAEs must be reported to the Sponsor no later than 3 calendar days from the 
day the site personnel became aware of the event or as per the investigative 
site’s local requirements, if the requirement is more stringent than those outlined.  
 
The date the site staff became aware the event met the criteria of an SAE must be recorded in the source 
document.  The Investigator will further report the SAE to the local IRB/EC according to the institution’s IRB/EC reporting requirements.  
8.2.1  Criteria and Guidelines for Reportable Events  
For the purposes of this clinical trial, the following events will be reported to the Sponsor for the duration 
of the trial:  
• All hospital admissions, including:  
o All SAEs occurring during a hospital admission outside of the original indication for admission (e.g. stroke, myocardial infarction, etc.)  
• Emergency department/hospital outpatient observation visits that  are cardiovascular in nature  
• All deaths  
• HFHs that occurred within 12 months prior to baseline  
• SAEs , ADEs, SADEs, and UADEs  
 Of the reportable events, the following events will be adjudicated by an independent CEC:  
• Events that could contribut e to primary endpoints for either trial arm, to determine which events 
meet primary endpoint qualification, including:  
o All cardiovascular hospitalizations, cardiovascular emergency department visits, and cardiovascular hospital outpatient visits , all defined as a hospital visit with the primary 
cause being cardiovascular in nature , as reported by the I nvestigator  
o All deaths  
o Any other hospitalizations  which, when reviewed by the Sponsor , could potentially  meet 
endpoint qualification  
• HFHs that occurred within 12 months  prior to baseline  
• All events that could contribute to the secondary safety endpoint for either trial arm including ADEs , SADEs, and UADEs  
 A list of anticipated AEs is included in sections 7.1.1 and 7.1.2.  The Sponsor will ensure that all applicable 
events  are reported to the relevant authorities as per regulations. The sites should notify the Sponsor of 
reportable AEs by cr eating and saving the applicable CRFs within the electronic data capture (EDC) 
system. The description of the AE , date of the AE, treatment and resolution of the AEs will be reported, as 
applicable, to the relevant authorities per regulations. Additional information may be requested, when 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 38 of 71 
  
required, by the Sponsor in order to support the reporting or adjudi cation of AEs . The Investigator  must 
notify the IRB/EC, if appropriate, in accordance with national and local laws and regulations, of the AEs reported to the Sponsor.  
8.2.2  Criteria and Guidelines for Non-R eportable Events  
The following events are not reportable  to the Sponsor : 
• Non- serious AEs  unrelated to the investigational device/procedure, including those occurring 
during the course of a hospitalization that are not the primary reason for the hospitalization  
• Non-cardiovascular or trauma events unrelated to HF , not resulting in a hospital admission  
• Minor outpatient non- cardiovascular  procedures , such as colonoscopy or cataract surgery  
8.2.3  Subject Death  
Subject deaths will be documented and reported to the Sponsor as soon as possible after the site 
becomes  aware of the event  via the applicable CRF. If a subject death is not reported within the required 
time, it will be considered a protocol deviation . 
 The CEC will review and classify all subject deaths . Notification of death must include a detailed 
statement of the pertinent event and be submitted on the applicable CRF. It is the Investigator ’s 
responsibility to notify the IRB/ EC per the IRB/EC  policy. Details of death and the following information, if 
available, should be provided to the Sponsor : 
• Date of death  
• Primary/organ cause of death  
• Any circumstances surrounding the death  
• Approximate time interval to death from the initiating event.  
• Autopsy report (if performed)  
• Whether it was trial device- and/or procedure- related  
8.2.4  U ADEs  
The Sponsor requires the Investigator to report any UADE to the Sponsor within 3 calendar days of the 
investigator’s knowledge of the event, unless local requirements are more stringent, and to the IRB/EC per IRB/EC requirements.  The same reporting requirement  applies to the investigational sites located in 
Canada.  
 In the case of a UADE reported to the Sponsor, t he Sponsor will take any steps necessary to investigate 
the event, and, as appropriate,  will be responsible for notifying  the FDA, Health Canada, and all  
participating IRBs/ECs and Investigator s within 10 working days . 
 Should the Sponsor determine, either through physician reports or in- house testing, that a UADE 
presents an unreasonable risk to participating patients, Sponsor will suspend the clinical investigation and notify  the FDA, Health Canada, and all participating IRBs/ECs  and Investigators . 
 Source records  
Source documents will be created and maintained by the investigational site team throughout the clinical trial. The data reported on the CRFs will be derived from, and be consistent with, these source documents, and any discrepancies will be explained in writing.  
 Relevant s ource documents for all reportable events which will be adjudicated by the CEC (see s ection 
8.2.1)  must be provided. Sites are responsible to acquire, de- identify and label records with subject ID 
and submit them to the Sponsor  in a timely manner.  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 39 of 71 
  
 Records Retention  
The Sponsor and the Principal Investigators will maintain the clinical trial documents as required. 
Measures  will be taken  to prevent accidental or premature destruction of these documents. The Principal 
Investigator or the Sponsor may transfer custody of records to another person/party and document the transfer at the investigational site or the Sponsor’s facility, as appropriate . 
 These documents must be retained by the investigational site for a period of two  years after  the 
conclusion of the  clinical trial and made available for monitoring or auditing by the Sponsor’s 
representative or representatives of the applicable regulatory agencies.  
 All original source documents must be stored for the maximum time required by the regulations at the 
hospital, research institute, or practice in question. If original source documents can no longer be maintained at the site, the Investigator  will notify the S ponsor.  
9 Clinical Data Handling 
The Sponsor will be responsible for the handling of clinical data generated in this trial, submitted by the 
site or obtained from Merlin.net ™. The Sponsor and/or its affiliates will be responsible for compiling and 
submitting all required reports to governmental agencies.  Data will be analyzed by the Sponsor and may 
be transferred to the Sponsor’s locations worldwide and/or any other worldwide regulatory authority in 
support of a market -approval application.  
 Protection of Personally Identifiable Information 
The Sponsor  respects and protects personally identifiable information collected or maintained for this 
clinical trial. The privacy of each subject and confidentiality of his/her information will be preserved in reports and when publishing any data. Confidentiality of data will be observed by all parties involved at all times throughout the clinical trial. All data will be secured against unauthorized access.  
 Data Management Plan  (DMP)  
A DMP will describe procedures used for data review, database creation and cleaning, and issuing and 
resolving data queries. If appropriate, the DMP may be updated throughout the clinical trial  duration. All 
revisions will be tracked and document controlled.  
 Subject  data will be captured in a validated EDC system hosted by the Sponsor  and compliant with FDA 
regulations . 
 Only authorized site personnel will be permitted to enter the CRF data through the EDC  system deployed 
by the Sponsor . An electronic audit trail will be used to track any subsequent changes of the entered 
data.  
 Document and Data Control  
9.3.1  Traceability of Documents and Data  
The Investigator  will ensure accuracy, completeness , legibility , and timeliness of the data reported to the 
Sponsor on the CRFs and in all required reports.  
9.3.2  Recording Data  
The CRFs will be reviewed by the authorized site personnel. An appropriate comment will be provided to 
explain  changes to data reported on the CRFs. 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 40 of 71 
  
10 Monitoring  
It is the responsibility of the S ponsor to ensure the clinical trial is conducted, recorded and reported 
according to the approved CIP, subsequent amendment(s), applicable regulations  and guidance 
documents.  
 Monitoring will be conducted according to the Sponsor ’s Clinical Monitoring work instruction.  Prior to 
beginning the clinical trial, the Sponsor  will contact the Investigator  or designee to discuss the clinical trial 
and data requirements. The Investigator  shall make subject and clinical trial records available to the 
clinical monitor for monitoring.  A designated monitor will periodically review the subject records and 
associated source documents.  
11 Compliance Statement  
 Statement of Compliance 
In addition to applicable regional or local laws and regulations, this  clinical trial will be conducted in 
compliance with the most current version of the World Medical Association (WMA) Declarat ion of Helsinki 
and 21 CFR Parts 50,  54, 56 and 812. In the event of any conflicts, local laws and regulations will have 
precedence and in such cases, good faith efforts will be made to adhere to the intent of the other documents.  
 The Investigator  will sign a Clinical Trial Agreement and agrees to be compliant with it. The Investigator  
will not start enrolling subjects or requesting informed consent from any subject prior to obtaining IRB/EC approval and relevant Regulatory  Authority approval, if applicable, and authorization from the S ponsor in 
writing for the clinical trial. 
If additional requirements are imposed by the IRB/EC or relevant Regulatory  
Authority, those requirements will be followed. If any action is taken by an IRB/EC  or a relevant 
Regulatory  Authority  with respect to the clinical trial, that information will be forwarded to the Sponsor . 
 
The Sponsor has taken up general liability insurance in accordance with the requirements of the 
applicable local laws. An a ppropriate Sponsor’s  country representative will be utilized to understand the 
requirements for the type of insurance that will be provided for subjects, and such information will be 
incorporated into the site informed consent  process , as applicable. If required, additional subject 
coverage or a clinical trial specific insurance will be provided by the Sponsor.  
 Quality Assurance A udits and Regulatory I nspections  
The Investigator  and/or delegate should contact the Sponsor  immediately upon notification of a regulatory 
authority  inspection at the site. A monitor or designee will assist the Investigator  and/or delegate in 
preparing for the audit.  The Sponsor may perform quality assurance audits, as required.  
 The Principal Investigator or institution will provide direct access to source and CRF data during and after 
the clinical trial for monitoring, audits, IRB/EC review and regulatory authority inspections, as required. 
The Principal Investigator or institution will obtain permission for direct access to source documents from 
the subject, hospital administration and national regulatory authorities before starting the clinical trial . 
 Repeated and Serious Non- Compliance  
The Sponsor will review compliance with the CIP and trends and deviations on a regular basis. In the 
event of repeated non- compliance or a one- time serious non- compliance, as determined by the Sponsor, 
a monitor  or designee will attempt to secure compliance by one or more of the following actions  and will 
document all attempts or actions : 
• Retrain applicable site research staff  
• Create a compliance plan  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 44 of 71 
  
Appendix  B: Acronyms  
 
6MHW  Six Minute Hall Walk  
ACC  American College of Cardiology  
ACE-I Angiotensin Converting Enzyme -Inhibitor  
ADE Adverse Device Effect  
ADHF  Acutely Decompensated Heart Failure  
AE Adverse Event  
AHA American Heart Association 
ARB Angiotensin Receptor Blocker  
ARNi  Angiotensin -Neprilysin Inhibitor  
BMI Body Mass Index  
BNP Brain Natriuretic Peptide  
CEC  Clinical Events Committee 
CHAMPION  CardioMEMS ™ HF Sensor Allows Monitoring of Pressures to 
Improve Outcomes in NYHA Functional Class III HF Patients  
CI Confidence Interval  
CIP Clinical Investigation Plan  
CMS  Center for Medicare and Medicaid Services  
CRF Case Report Form  
CRT Cardiac Resynchronization Therapy  
CRT-D Cardiac Resynchronization Therapy – Defibrillator  
CRT-P Cardiac Resynchronization Therapy – Pacemaker  
DMP  Data Management Plan  
DSMB  Data Safety Monitoring Board  
DSRC  Device/System Related Complication  
EC Ethics Committee  
EDC  Electronic Data Capture  
EF Ejection Fraction  
eGFR  Glomerular Filtration Rate  
EQ-5D-5L EuroQol 5- Dimension, 5- Level  
FDA Food and Drug Administration  
GDMT  Guideline Directed Medical Therapy  
GUIDE -HF Hemodynamic -GUIDEd Management of Heart Failure  
HF Heart Failure  
HFH Heart Failure Hospitalization  
HFpEF  Heart Failure with Preserved Ejection Fraction  
HFrEF  Heart Failure with Reduced Ejection Fraction  
HR Hazard Ratio  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IFU Instructions for Use  
IRB Institutional Review Board  
KCCQ -12 Kansas City Cardiomyopathy Questionnaire  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 45 of 71 
  
LSM Least Squares Means  
LVAD  Left Ventricular Assist Device 
LVEF  Left Ventricular Ejection Fraction  
MAC  Medicare Administrative Contractor  
MEMS  Micro -ElectroMechanical Systems  
NT-proBNP  N-Terminal pro -Brain Natriuretic Peptide  
NYHA  New York Heart Association 
PA Pulmonary Artery  
PAS Post-Approval Study  
PCWP  Pulmonary Catheter Wedge Pressure  
PMA  Pre-Market Approval  
RHC  Right Heart Catheterization  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
TOST  Two, One -Sided Test  
UADE  Unanticipated Adverse Device Effect  
VAS Visual Analogue Scale  
VRDC  Virtual Research Data Center  
WMA  World Medical Association  
  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 47 of 71 
  
Note:  A planned hospitalization for a pre- existing condition, or a procedure required by the 
CIP is not considered an SAE. 
• Adverse Device Effect (ADE) : An AE related to the use of an investigational medical device.  
This definition includes AEs resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  This definition includes any event resulting from the use error or from intentional 
misuse of the investigational medical device.  
• Serious Adverse Device Effect  (SADE) : ADE that has resulted in any of the consequences 
characteristic of a serious AE. 
• Unanticipated A dverse Device Effect  (UADE) : As defined in 21 CFR §812.3, any serious 
adverse effect on health or safety or any life- threatening problem or death caused by, or 
associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the CIP or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.   
• Non-AE Device Issue: any instance when the device fails to perform or does not function 
properly without an associated an adverse clinical outcome.  
• Device/System Related Complication (DSRC) : An AE that is related or possibl y related to the 
system (CardioMEMS ™ PA Sensor or other components of the CardioMEMS ™ HF System) and 
has at least one of the following characteristics:  
o is treated with invasive means (other than intramuscular medication or a right heart catheterization which is used for diagnostic purposes)  
o resulted in the death of the subject  
o resulted in the explant of the device  
 
  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 50 of 71 
  
Table D1: Estimated Composite Event Rates from Previous HF Studies  
   
   
 
 
      
    
 
         
          
         
         
         
         
        
       
         
         
           
     
  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 56 of 71 
  
Appendix I: Subject -Reported Outcome Measures  
 The Trial Coordinator or designee will administer  subject -reported outcome questionnaires. It is important 
the subject understands the meaning of all words and instructions in the questionnaires. The subject should be instructed to ask any questions about the questionnaires if  further explanation is needed. It is 
recommended that the subject -reported outcome measures are issued prior to all other procedures during 
each visit. Once the questionnaires are completed, the Trial  Coordinator or designee will review for 
completeness to verify that all questions have been answered according to the directions provided.  
 The following subject -reported outcome measures will be collected according to the trial requirements : 
• EQ-5D-5L to be obtained at baseline, 6 months and 12 months  
• KCCQ -12 to be obtained at baseline, 6 months and 12 months  
 EQ-5D-5L 
The EQ -5D-5L is a standardized measure of health status developed by the EuroQol Group in order to 
provide a simple, generic measure of health for clinical and economic appraisal. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of healthcare as well as in population health surveys. The questionnaire will take approximately two minutes to complete.  
 The EQ -5D-5L consists of two  components – the EQ -5D-5L descriptive system and the EQ Visual 
Analogue scale (VAS). For the descriptive system, five  dimensions are measured (mobility, self -care, 
usual activities, pain/discomfort, and anxiety/depression). Each dimension has five  levels: 1=none, 
2=slight, 3=moderate, 4=severe, and 5=extreme. The respondent indicates his or her health state by ticking in the box against the most appropriate statement in each of the five  dimensions. The VAS is 
scored from 0 (worst health) to 100 (best health) .  
 
KCCQ -12 
The KCCQ -12 is a standardized, validated ( 53), and disease- specific health status measure for HF 
patients. It is a self -administered questionnaire that quantifies physical limitations, symptoms, self -
efficacy, social interference and quality of life. It is shown to have high test -retest reliability and high 
responsiveness. It is prognostic of both clinical events and costs. The KCCQ -12 will be utilized as a 
performance measure of healthcare quality. It provides a reliable and effective tool to assess whether HF 
patients’ conditions have changed over time. The questionnaire has twelve questions and takes 
approximately three minutes to complete.   
 
 

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 59 of 71 
  
Appendix L: Enrollment Flow Chart  
 
 
  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 65 of 71 
  
Secondary 
Endpoints  GUIDE -HF Randomized Arm: The secondary effectiveness endpoints, to be compared 
between the Treatment and Control Groups , are: 
• Composite of recurrent HFHs or emergency department/hospital outpatient observation visits for intravenous diuretic therapy  
• Health status at baseline, 6, and 12 months post -implantation as assessed by 
the EuroQol 5- Dimension, 5- Level (EQ -5D-5L) Questionnaire  
• Health status at baseline, 6, and 12 months post -implantation as assessed by 
the Kansas City Cardiomyopathy Questionnaire (KCCQ -12) 
• Six Minute Hall Walk (6MHW) test at baseline, 6, and 12 months post -
implantation  
• In addition, the individual components of the primary endpoint will each be evaluated as descriptive secondary effectiveness endpoints:  
o HFHs at 12 months post -implantation  
o Emergency department/hospital outpatient observation visits for intravenous diuretic therapy at 12 months post -implantation  
o All-cause mortality at 12 months post -implantation  
The secondary safety endpoint is freedom from device/system related complications (DSRCs) at 12 months post -implantation. The secondary safety endpoint will be 
evaluated for all subjects enrolled in the Randomized Arm (i.e. with an attempted implant, whether successful or unsuccessful) and reported for the entire subject cohort and by subject group.  
 
GUIDE -HF Single Arm: The secondary effectiveness endpoints are:  
• Composite of recurrent HFHs or emergency department/hospital outpatient 
observation visits for intravenous diuretic therapy at 12 months post -
implantation  
• HFHs at 12 months post -implantation compared to HFHs in the 12 months prior 
to implantation. All subjects who receive a CardioMEMS ™ PA Sensor implant 
will be included in the analysis of this endpoint.  
• In addition, the individual components of the primary endpoint will each be evaluated as descriptive secondary effectiveness endpoints:  
o HFHs at 12 months post -implantation  
o Emergency department/hospital outpatient observation visits for intravenous diuretic therapy at 12 months post -implantation  
o All-cause mortality at 12 months post -implantation  
The secondary safety endpoint is freedom from DSRCs at 12 months post -implantation. 
The secondary safety endpoint will be evaluated for all subjects enrolled in the Single Arm (i.e. with an attempted implant, whether successful or unsuccessful) and reported for the entire subject cohort and by subject group.  
Inclusion Criteria  1. Diagnosis and treatment for HF (regardless of LVEF) for > 90 days prior to the date of consent:  
a. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current AHA/American College of Cardiology (ACC) guidelines as standard- of-care for HF therapy in the United 
States, with any intolerance doc umented.  
2. GUIDE -HF Randomized Arm Only : NYHA Class II, III or IV HF symptoms 
documented within 30 days prior to consent.  

 Study Document No .:  
Study Name: GUIDE -HF IDE  
 Clinical Investigation  Plan 
 
 
 
 Page 66 of 71 
  
3. GUIDE -HF Single Arm Only : NYHA Class III HF symptoms documented within 30 
days prior to consent.  
4. HFH within 12 months prior to consent and/or elevated NT -proBNP (or BNP) within 
30 days prior to consent defined as:  
a. Subjects with LVEF ≤ 40%: NT -proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL).  
b. Subjects with LVEF > 40%: NT -proBNP ≥ 700 pg/mL (or BNP ≥ 175 pg/mL).  
c. Thresholds for NT -proBNP and BNP (for both LVEF ≤ 40% and LVEF > 40%) 
will be corrected for BMI using a 4% reduction per BMI unit over 25 kg/m2  
5. ≥ 18 years of age  
6. Chest circumference of < 65 inches, if BMI is > 35 kg/m2 
7. Written informed consent obtained from subject  
8. Willing and able to upload PA pressure information and comply with the follow -up 
requirements  
Exclusion Criteria  1. Intolerance to all neuro- hormonal antagonists (i.e., intolerance to angiotensin 
converting enzyme- inhibitors (ACE -I), angiotensin receptor blockers (ARB), 
angiotensin- neprilysin inhibitors (ARNi),  hydralazine/isosorbide dinitrate,  and beta-
blockers)  
2. ACC/AHA Stage D refractory HF (including having received or currently receiving 
pharmacologic circulatory support with inotropes)  
3. Received or are likely to receive an advanced therapy (e.g., mechanical circulatory 
support or cardiac transplant) in the next 12 months  
4. NYHA Class IV HF patients with:  
a. Continuous or chronic use of scheduled intermittent inotropic therapy for HF 
and an INTERMACS level of ≤ 4, OR  
b. Persistence of fluid overload with maximum (or dose equivalent) diuretic intervention  
5. Glomerular Filtration Rate (eGFR) < 25 mL/min/1.73m
2 and non-responsive to 
diuretic therapy, or receiving chronic dialysis  
6. Inability to tolerate or receive dual antiplatelet therapy or anticoagulation therapy for one month post -implantation  
7. Significant congenital heart disease that has not been repaired and would prevent implantation of the CardioMEMS™ PA Sensor  
8. Implanted with mechanical right heart valve(s)  
9. Unrepaired severe valvular disease  
10. Pregnant or planning to become pregnant in the next 12 months  
11. An active, ongoing infection, defined as being febrile, an elevated white blood cell count, on intravenous antibiotics, and/or positive cultures (blood, sputum or urine).  
12. History of current or recurrent (≥ 2 episodes  within 5 years prior to consent ) 
pulmonary emboli and/or deep vein thromboses  
13. Major cardiovascular event (e.g., unstable angina, myocardial infarction, percutaneous coronary intervention, open heart surgery, or stroke, etc.) within 90 days prior to consent  
14. Implanted with Cardiac Resynchronization Therapy (CRT) -Pacemaker (CRT -P) or 
CRT-Defibrillator (CRT -D) for less than 90 days prior to consent  
15. Enrollment into another trial with an active treatment arm 
16. Anticipated life expectancy of < 12 months  
17. Any condition that, in the opinion of the Investigator, would not allow for utilization of the CardioMEMS ™ HF System to manage the subject using information gained 
from hemodynamic measurements to adjust medications, including the presence of 
unexpectedly severe pulmonary hypertension (e.g., trans -pulmonary gradient >15) 
at implant RHC, a history of non- compli ance, or any condition that would preclude 
CardioMEMS ™ PA Sensor implantation  
